Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity
European Journal of Pharmaceutics and Biopharmaceutics · 2023
DOI: 10.1016/j.ejpb.2023.08.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Thomas Vazquez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France. Hauptthemen laut MEDLINE: Immunity, Mucosal, AIDS Vaccines, T-Lymphocytes, Helper-Inducer, HIV Antibodies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Commission, Central University of Technology, FP7 Health.
Abstract (Originalsprache)
Mucosal surfaces serve as the primary entry points for pathogens such as SARS- CoV-2 coronavirus or HIV in the human body. Mucosal vaccination plays a crucial role to successfully induce long-lasting systemic and local immune responses to confer sterilizing immunity. However, antigen formulations and delivery methods must be properly selected since they are decisive for the quality and the magnitude of the elicited immune responses in mucosa. We investigated the significance of using particulate antigen forms for mucosal vaccination by comparing VLP- or protein- based vaccines in a mouse model. Based on a mucosal prime-boost immunization protocol combining (i) HIV- pseudotyped recombinant VLPs (HIV-VLPs) and (ii) plasmid DNA encoding HIV- VLPs (pVLPs), we demonstrated that combination of intranasal primes and intravaginal boosts is optimal to elicit both humoral and cellular memory responses in mucosa. Interestingly, our results show that in contrast to proteins, particulate antigens induce high-quality humoral responses characterized by a high breadth, long-term neutralizing activity and cross-clade reactivity, accompanying with high T follicular helper cell (TFH) response. These results underscore the potential of a VLP-based vaccine in effectively instigating long-lasting, HIV-specific immunity and point out the specific role of particulate antigen form in driving high-quality mucosal immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France.
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical I…
- Université de Strasbourg, Fédération de médecine Translationnelle de Strasbourg, INSERM U1109, F-67000, France.
Förderung
- European Commission
- Central University of Technology
- FP7 Health
Zitieren
APA
Vazquez, T., Torrieri-Damard, L., Pitoiset, F., Levacher, B., Vigneron, J., Mayr, L., Brimaud, F., Bonnet, B., Moog, C., Klatzmann, D., & Bellier, B. (2023). Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.08.014
Vancouver
Vazquez T, Torrieri-Damard L, Pitoiset F, Levacher B, Vigneron J, Mayr L, et al. Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.08.014
BibTeX
@article{Vazquez2023,
author = {Vazquez, Thomas and Torrieri-Damard, Léa and Pitoiset, Fabien and Levacher, Béatrice and Vigneron, James and Mayr, Luzia and Brimaud, Faustine and Bonnet, Benjamin and Moog, Christiane and Klatzmann, David and Bellier, Bertrand},
title = {Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
doi = {10.1016/j.ejpb.2023.08.014}
}
EUVIMED